This work is licensed under a
Creative Commons Attribution 4.0 International License
 P.M. Mannucci, M.E. Mancuso, M. Franchini, Tailoring hemostatic therapies to lower inhibitor development in previously untreated patients with severe hemophilia A, J. Thromb. Haemost. 14 (2016)1330-1336.DOI: https://doi.org/10.1111/jth.13356
 J. Hartmann J, S.E. Croteau, 2017 Clinical trials update: Innovations in hemophilia therapy, Am. J. Hematol. 91 (2016)1252-1260.DOI: https://doi.org/10.1002/ajh.24543
 S.L. Meeks, G. Batsuli, Hemophilia and inhibitors: current treatment options and potential new therapeutic approaches, Hematology Am. Soc. Hematol. Educ. Program. 2016 (2016) 657-662.DOI: https://doi.org/10.1182/asheducation-2016.1.657
 M. Shima, D. Lillicrap, R. Kruse-Jarres, Alternative therapies for the management of inhibitors, Haemophilia. 22(S5) (2016) 36-41.
 P.E. Monahan, Emerging genetic and pharmacologic therapies for controlling hemostasis: beyond recombinant clotting factors, Hematology Am. Soc. Hematol. Educ. Program. 2015 (2015) 33-40.DOI: https://doi.org/10.1182/asheducation-2015.1.33
 N. Machin, M.V. Ragni, An investigational RNAi therapeutic targeting antithrombin for the treatment of hemophilia A and B, J. Blood Med. 9 (2018) 135-140.DOI: https://doi.org/10.2147/jbm.s159297
 K.P. Pratt, Engineering less immunogenic and antigenic FVIII proteins, Cell Immunol. 301 (2016) 12-17.
 G. Young, J.N. Mahlangu, Extended half-life clotting factor concentrates: results from published clinical trials, Haemophilia. 22(S5) (2016) 25-30.DOI: https://doi.org/10.1111/hae.13028
 P.M. van Helden et al., Maintenance and break of immune tolerance against human factor VIII in a new transgenic hemophilic mouse model, Blood. 118 (2011) 3698-3707.DOI: https://doi.org/10.1182/blood-2010-11-316521
 S.S. Dhadwar et al., Repeated oral administration of chitosan/DNA nanoparticles delivers functional FVIII with the absence of antibodies in hemophilia A mice, J. Thromb. Haemost. 8 (2010) 2743-2750.DOI: https://doi.org/10.1111/j.1538-7836.2010.04116.x
 S. Mathieu S et al., Challenges of the management of severe hemophilia A with inhibitors: two case reports emphasizing the potential interest of a high-purity human Factor VIII/von Willebrand factor concentrate and individually tailored prophylaxis guided by thrombin-generation test, Blood Coagul. Fibrinolysis. 26 (2015).DOI: https://doi.org/10.1097/mbc.0000000000000300
 M.D. Tarantino et al., Recombinant porcine sequence factor VIII (rpFVIII) for acquired haemophilia A: practical clinical experience of its use in seven patients, Haemophilia. 23 (2017) 25-32.DOI: https://doi.org/10.1111/hae.13040
 C. Hart, S. Schmid, Coagulation disorders in the intensive care unit - what is new?, Dtsch. Med. Wochenschr. 141 (2016) 777-780.
 J. Mahlangu et al., Efficacy and safety of rVIII-SingleChain: results of a phase 1/3 multicenter clinical trial in severe hemophilia A, Blood. 128 (2016) 630-637.
 J.A. Abrantes et al., Elucidation of Factor VIII Activity Pharmacokinetics: A Pooled Population Analysis in Patients With Hemophilia A Treated With Moroctocog Alfa, Clin. Pharmacol. Ther. 102 (2017) 977-988.DOI: https://doi.org/10.1002/cpt.716
 D. Lillicrap et al., Porcine recombinant factor VIII (Obizur; OBI-1; BAX801): product characteristics and preclinical profile. Haemophilia, 2015. Information on: https://www.ncbi.nlm.nih.gov/pubmed/26278557. Accessed: 12.04.(2018).DOI: https://doi.org/10.1111/hae.12784
 K.A. Shetty et al., Factor VIII associated with lipidic nanoparticles retains efficacy in the presence of anti-factor VIII antibodies in hemophilia A mice, Biopharm. Drug Dispos. 37 (2016) 409-420.DOI: https://doi.org/10.1002/bdd.2023
 M. Franchini, P.M. Mannucci, Efficacy and safety of a recombinant factor VIII produced from a human cell line (simoctocog alfa), Expert Opin. Drug Saf. 16 (2017) 405-410.DOI: https://doi.org/10.1080/14740338.2017.1285281
 J. Yoon et al., FVIII-specific human chimeric antigen receptor T-regulatory cells suppress T- and B-cell responses to FVIII, Blood. 129 (2017) 238-245.DOI: https://doi.org/10.1182/blood-2016-07-727834
 J. Salas et al., Enhanced Pharmacokinetics of Factor VIIa as a Monomeric Fc Fusion, Thromb. Res. 135 (2015) 970-976.
 K.M. Hansson et al., Effects of recombinant human prothrombin on thrombin generation in plasma from patients with hemophilia A and B, J. Thromb. Haemost. 13 (2015)1293-1300.DOI: https://doi.org/10.1111/jth.12997
 V. Bhat et al., Improved coagulation and haemostasis in haemophilia with inhibitors by combinations of superFactor Va and Factor VIIa, Thromb. Haemost. 115 (2016) 551-561.DOI: https://doi.org/10.1160/th15-07-0525
 L.A. George et al., Correction of human hemophilia A whole blood abnormalities with a novel bypass agent: zymogen-like FXa(I16L), J. Thromb. Haemost. 13 (2015) 1694-1698.DOI: https://doi.org/10.1111/jth.13059
 J.Y. Chang et al., Studies on the mechanism of action of the aptamer BAX499, an inhibitor of tissue factor pathway inhibitor, Thromb. Res. 130(3) (2012) e151-157.
 P. Margaritis. Gene-based continuous expression of FVIIa for the treatment of haemophilia, Front. Biosci. (Schol Ed). 4 (2012) 287-299.DOI: https://doi.org/10.2741/s269
 K.E. Brummel-Ziedins et al., Activated protein C inhibitor for correction of thrombin generation in hemophilia A blood and plasma, J. Thromb. Haemost. 9 (2011) 2262-2267.
 C.E. McCarthy et al., Updated analysis: central venous access device infection rates in an expanded cohort of paediatric patients with severe haemophilia receiving prophylactic recombinant tissue plasminogen activator, Haemophilia. 22 (2016).DOI: https://doi.org/10.1111/hae.12772